| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +166K | 29.2% | $373.73 | +$61.9M |
| Sells | 11 | -403K | 70.8% | $358.57 | -$144M |
| Net | -10 | -237K | -41.7% | -$82.4M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Baker Bros. Advisors Lp | Director | $764M | +$61.9M | +8.82% | Aug 18, 2025 |
| Rebecca Taub | Director | $452M | -$27.8M | -5.79% | Aug 11, 2025 |
| Paul A. Friedman | Director | $357M | -$75.1M | -17.4% | Aug 13, 2025 |
| Fred B. Craves | Director | $123M | -$7.41M | -5.7% | Mar 12, 2025 |
| William John Sibold | President and CEO, Director | $45.7M | -$6.82M | -13% | Sep 9, 2025 |
| Richard S. Levy | Director | $7.08M | -$3.25M | -31.5% | Jun 20, 2025 |
| Alex G. Howarth | Chief Financial Officer | $5.74M | Jan 23, 2024 | ||
| Brian J. Lynch | SVP and General Counsel | $5.33M | Jan 23, 2024 | ||
| Carole Huntsman | Chief Commercial Officer | $4.02M | -$932K | -18.8% | Mar 5, 2025 |
| Remy Sukhija | Chief Commercial Officer | $3.66M | Jan 16, 2023 | ||
| Shannon T. Kelley | General Counsel | $3.45M | -$694K | -16.7% | Aug 18, 2025 |
| Mardi Dier | SVP and CFO | $3.37M | -$721K | -17.6% | Mar 10, 2025 |
| David Soergel | Chief Medical Officer | $2.57M | May 15, 2025 | ||
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | $2M | -$5.39M | -73% | Mar 5, 2025 |
| Kenneth Bate | Director | $968K | -$10.8M | -91.8% | Aug 15, 2025 |
| James M. Daly | Director | $877K | -$5.38M | -86% | Jun 20, 2025 |
| Jacqualyn A. Fouse | Director | $366K | Jun 20, 2025 | ||
| Daniel J. Brennan | Director | $323K | Aug 1, 2025 | ||
| Bay City Capital Llc | 10%+ Owner | $308K | Dec 3, 2021 | ||
| Keith R. Gollust | Director | Jun 16, 2022 | |||
| Raymond Cheong | Director | Jun 15, 2023 | |||
| David Milligan | Director | Jun 16, 2022 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|